<code id='7EF57A7874'></code><style id='7EF57A7874'></style>
    • <acronym id='7EF57A7874'></acronym>
      <center id='7EF57A7874'><center id='7EF57A7874'><tfoot id='7EF57A7874'></tfoot></center><abbr id='7EF57A7874'><dir id='7EF57A7874'><tfoot id='7EF57A7874'></tfoot><noframes id='7EF57A7874'>

    • <optgroup id='7EF57A7874'><strike id='7EF57A7874'><sup id='7EF57A7874'></sup></strike><code id='7EF57A7874'></code></optgroup>
        1. <b id='7EF57A7874'><label id='7EF57A7874'><select id='7EF57A7874'><dt id='7EF57A7874'><span id='7EF57A7874'></span></dt></select></label></b><u id='7EF57A7874'></u>
          <i id='7EF57A7874'><strike id='7EF57A7874'><tt id='7EF57A7874'><pre id='7EF57A7874'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:73
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          After sickle
          After sickle

          MollyFerguson/STATTheapprovalFridayofBluebirdBio’sgenetherapyforsicklecelldiseaseshouldhavebeenamome

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          Diversifying clinical trials isn't enough to close racial gaps: study

          AdobeParticipationinaclinicaltrialisoftenconsideredsomethingofanequalizerinmedicine.Researchershavep